Padcev and advanced urothelial cancer

Padcev received accelerated approval for the treatment of locally advanced or metastatic urothelial cancer announced on Dec. 18, 2019.It specifically targets the cell adhesion molecule Nectin-4, which is highly expressed in urothelial cancers. “Antibody-drug conjugates are strategic tools in the targeted treatment of cancer. These conjugates combine the ability of monoclonal antibodies to target specific […]

Read More